 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA |
| Siho Kim, Jinhyun Cho, Won Park, Sang-Hee Choi, Woongyang Park, Kee-Taek Jang, Jeeyun Lee |
|
Precis Future Med. 2017;1(1):52-57. Published online March 31, 2017 DOI: https://doi.org/10.23838/pfm.2017.00108 |
|
HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA Precision and Future Medicine. 2017;1(1):52-57  TP53 mutation and/or overexpression of the HER2 receptor are strong indicators of poor prognosis in both node-negative and node-positive early breast cancer European Journal of Cancer. 2002;38(11):S107-S108 PR84 FULVESTRANT COMBINED WITH CAPECITABINE MAY BE EFFECTIVE AND WELL TOLERATED FOR PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER The Breast. 2015;24:S50-S51 Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer Cancer Treatment Reviews. 2018;63:144-155 HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer Breast Cancer. 2018;25(5):605-613 TP53 Promoter Methylation in Primary Glioblastoma: Relationship with TP53 mRNA and Protein Expression and Mutation Status DNA and Cell Biology. 2014;33(4):217-226 Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma Diagnostic Cytopathology. 2011;39(5):328-332 TP53 mutations on circulating cell-free DNA EBioMedicine. 2016;10:15-16 Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution Breast Cancer Research and Treatment. 2017;166(3):911-917 Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients Medical Oncology. 2016;33(10): |
